Parallel Advisors’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Parallel Advisors’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-4	Closed	-$164	–	3501
2024 Q2	$164	Hold	4	–	–	﹤0.01%	3216
2024 Q1	$169	Hold	4	–	–	﹤0.01%	3169
2023 Q4	$170	Buy	+4	New	+$115	﹤0.01%	3188
2023 Q1	–	Sell	-3	Closed	-$95	–	3528
2022 Q4	$95	Buy	+3	New	+$85	﹤0.01%	3265
2022 Q1	–	Sell	-9	Closed	–	–	3344
2021 Q4	$0	Buy	+9	New	+$318	﹤0.01%	3347

Other funds holding CERE

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Parallel Advisors's CERE Position: Q3 2024 in Review

Parallel Advisors sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 4 shares — an estimated $164 sold.

Parallel Advisors first reported a position in CERE in Q4 2021 and held it in 5 quarters. The position peaked at $170 in Q4 2023. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

Parallel Advisors reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Parallel Advisors sold 4 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $164.
Parallel Advisors first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2021 and held it in 5 quarters.
Parallel Advisors's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $170 in Q4 2023.
2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Parallel Advisors's 13F filing for Q3 2024, filed 13 Nov 2024.